Sepetaprost

Sepetaprost
Clinical data
Other namesSTN-1012600
Legal status
Legal status
  • Investigational
Identifiers
  • propan-2-yl 4-[(3S,5aR,6R,7R,8aS)-6-[(E,3R)-4-(2,5-difluorophenoxy)-3-hydroxybut-1-enyl]-7-hydroxy-3,4,5,5a,6,7,8,8a-octahydro-2H-cyclopenta[b]oxepin-3-yl]butanoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H36F2O6
Molar mass482.565 g·mol−1
3D model (JSmol)
  • CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@H]([C@@H]2/C=C/[C@H](COC3=C(C=CC(=C3)F)F)O)O)OC1
  • InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1
  • Key:BKVUSNOUTQMSBE-XCMGCKIWSA-N

Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension.[1] It is an agonist of the prostaglandin EP3 and F receptors.[2]

References

  1. ^ "Sepetaprost - Santen Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L (April 2023). "FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma". Experimental Eye Research. 229: 109415. doi:10.1016/j.exer.2023.109415. PMID 36803996.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.